Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry
Copyright © 2020 Elsevier B.V. All rights reserved..
N6-[(S)-1- (phenyl)-propyl]-adenine riboside (YZG-331) is being developed as a novel sedative and hypnotic agent. The hydroxylated metabolites of YZG-331 have the same mass transition ion pair, making their determination in blood challenging. In this study, a rapid and sensitive liquid chromatography-tandem mass spectrometry method was developed for the simultaneous determination of YZG-331 and its metabolites M1 (hydrolysis), M2 and M4 (hydrolysis and hydroxylation), M3, M5 and M6 (hydroxylation) in monkey blood. Propranolol was used as the internal standard (IS). Blood samples were prepared using a simple protein precipitation with acetonitrile. The chromatographic separation was performed on an Eclipse Plus C18 column (2.1 × 50 mm, 3.5 μm) at a flow rate of 0.3 mL/min with a gradient mobile phase of methanol/water containing 0.5 % formic acid (v/v). Detection was carried out on a triple quadrupole mass spectrometer in positive ion multiple reaction monitoring mode. The optimized mass transition ion pairs for quantitation were 386→254 for YZG-331, 254→136 for M1, 270→136 for M2 and M4, 402→136 for M3, M5 and M6 and 260→183 for IS. Acceptable linearity was obtained for the analytes over the range of 15-2000 ng/mL for YZG-331, 3-400 ng/mL for M1-M6. The lower limits of the quantification were 15 ng/mL for YZG-331, 3 ng/mL for M1-M6. The intra- and inter-day precisions wre within 10.5 % for all analytes, while the accuracy ranged from -8.3 %-8.8 %. There was no obvious matrix effect and the recoveries of the analytes were 90.6 %-118.2 %. The analytes were proved to be stable during all sample storage, preparation and analytic procedures. The sensitive and rapid LC-MS/MS method for YZG-331 in monkey blood has been applied to pharmacokinetic studies of YZG-331 in monkeys. The oral bioavailability of YZG-331 in monkeys is 74.1 %.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:193 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical and biomedical analysis - 193(2021) vom: 30. Jan., Seite 113720 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Xiao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adenosine |
|---|
| Anmerkungen: |
Date Completed 17.06.2021 Date Revised 17.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jpba.2020.113720 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317574981 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317574981 | ||
| 003 | DE-627 | ||
| 005 | 20231225163543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jpba.2020.113720 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317574981 | ||
| 035 | |a (NLM)33190084 | ||
| 035 | |a (PII)S0731-7085(20)31606-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Xiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2021 | ||
| 500 | |a Date Revised 17.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a N6-[(S)-1- (phenyl)-propyl]-adenine riboside (YZG-331) is being developed as a novel sedative and hypnotic agent. The hydroxylated metabolites of YZG-331 have the same mass transition ion pair, making their determination in blood challenging. In this study, a rapid and sensitive liquid chromatography-tandem mass spectrometry method was developed for the simultaneous determination of YZG-331 and its metabolites M1 (hydrolysis), M2 and M4 (hydrolysis and hydroxylation), M3, M5 and M6 (hydroxylation) in monkey blood. Propranolol was used as the internal standard (IS). Blood samples were prepared using a simple protein precipitation with acetonitrile. The chromatographic separation was performed on an Eclipse Plus C18 column (2.1 × 50 mm, 3.5 μm) at a flow rate of 0.3 mL/min with a gradient mobile phase of methanol/water containing 0.5 % formic acid (v/v). Detection was carried out on a triple quadrupole mass spectrometer in positive ion multiple reaction monitoring mode. The optimized mass transition ion pairs for quantitation were 386→254 for YZG-331, 254→136 for M1, 270→136 for M2 and M4, 402→136 for M3, M5 and M6 and 260→183 for IS. Acceptable linearity was obtained for the analytes over the range of 15-2000 ng/mL for YZG-331, 3-400 ng/mL for M1-M6. The lower limits of the quantification were 15 ng/mL for YZG-331, 3 ng/mL for M1-M6. The intra- and inter-day precisions wre within 10.5 % for all analytes, while the accuracy ranged from -8.3 %-8.8 %. There was no obvious matrix effect and the recoveries of the analytes were 90.6 %-118.2 %. The analytes were proved to be stable during all sample storage, preparation and analytic procedures. The sensitive and rapid LC-MS/MS method for YZG-331 in monkey blood has been applied to pharmacokinetic studies of YZG-331 in monkeys. The oral bioavailability of YZG-331 in monkeys is 74.1 % | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adenosine | |
| 650 | 4 | |a LC–MS/MS | |
| 650 | 4 | |a Metabolites | |
| 650 | 4 | |a Monkey | |
| 650 | 4 | |a Pharmacokinetic | |
| 650 | 4 | |a YZG-331 | |
| 650 | 7 | |a YZG-331 |2 NLM | |
| 650 | 7 | |a Adenosine |2 NLM | |
| 650 | 7 | |a K72T3FS567 |2 NLM | |
| 700 | 1 | |a Jiang, Jianwei |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Xiaoxu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuke |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Chengbo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jianjun |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jiangong |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical and biomedical analysis |d 1983 |g 193(2021) vom: 30. Jan., Seite 113720 |w (DE-627)NLM012641928 |x 1873-264X |7 nnns |
| 773 | 1 | 8 | |g volume:193 |g year:2021 |g day:30 |g month:01 |g pages:113720 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jpba.2020.113720 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 193 |j 2021 |b 30 |c 01 |h 113720 | ||